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idea that, especially in the absence of a mea-
surement of CSF pressure (ie, in those pa-
tients without spinal cord drainage),
central venous pressure (CVP) can perhaps
be used as a substitute, in this context, for
CSF pressure. We think it is unlikely that
CSF pressure can ever be less than CVP,
but the exact relationship between them
may not be entirely straightforward despite
the observation that CSF and CVP correlate
closely during normal cardiopulmonary cir-
culation.1,2 The relevance of a high CVP in
the context of spinal cord perfusion is ex-
plained by the fact that the arterial pressure
of the inflow to the spinal cord after seg-
mental artery sacrifice is only a fraction of
systemic mean arterial pressure (MAP), as
explained next.
We think that establishing an index for
assessing the adequacy of the postoperative
SCPP is an excellent idea. However, among
the parameters readily available in the
clinical setting (in the operating room and
intensive care unit), we believe the most im-
portant variable to adequately assess SCPP
is missing: the actual inflow arterial pressure
in the collateral system supplying the most
vulnerable region of the spinal cord. To ob-
tain this pressure, we have recently adapted
a method we developed in our laboratory:
we insert a small catheter directly into the
stump of a thoracic or lumbar segmental ar-
tery during surgery to measure the pressure
in the collateral circulation during the oper-
ation, and for a variable interval postopera-
tively when possible.
After extensive segmental artery occlu-
sion, when inflow is provided predominantly
by the collateral network, the arterial input for
SCPP routinely decreases to levels as low as
20% of MAP, according to our experimental
studies.3,4 We have confirmed similarly low
levels of inflow SCPP (20% of MAP) tran-
siently in patients after segmental artery sacri-
fice using a catheter placed in L1. In patients
with an L1 catheter and CSF drainage, an ac-
curate SCPP can be calculated as SCPP5 L1
pressure – CSF pressure.
The acceptable minimum SCPP—the
value recorded at the end of operation in the
presence of intact function as documented
by SSEP/MEP monitoring—could be used
as a baseline when calculating an adequate
flowforpostoperative follow-up:SCPP index
5 current SCPP – minimum SCPP.
Such an SCPP index could be monitored
along with the usual vital signs, and
changes in hemodynamics instituted if it de-
creases below zero. A negative SCPP index
would indicate that spinal cord perfusion is
below safe levels and trigger corrective
measures, such as increasing MAP and de-
creasing CSF or CVP to improve perfusion;
the target SCPP index should be zero or
more at all times. An additional CONSID-
ERATION is that the patient may warm sig-
nificantly after surgery, and increases in
metabolic rate in the cord, as well as other
tissues supplied by the collateral flow,
THAN AT BASELINE. For calculation of
A SCPP index in the absence of CSF pres-
sure measurements, CVP could be
substituted.
In the absence of direct monitoring,
however, we think that routine consider-
ation of AN INDIVIDUAL’S preoperative
MAP would be a simplified way for person-
nel charged with the care of patients after an-
eurysm surgery which poses a risk of
paraplegia to monitor the minimum sys-
temic pressures necessary to provide ade-
quate spinal cord perfusion without their
being required to have a sophisticated un-
derstanding of spinal cord perfusion require-
ments. In general, we think that a CVP less
than 10 mm Hg would be acceptable, but
a high CVP may have to be treated more ag-
gressively if arterial pressure is low. To raise
the arterial pressure, we would—in view of
the need to keep the CVP low—advocate
the use of pharmacologic agents such as
epinephrine or norepinephrine rather than
using volume infusions.
We thank Dr Augoustides for raising
these issues and the editorial board for the
opportunity of discussing them.
Christian D. Etz, MD
Randall B. Griepp, MD
Mount Sinai School of Medicine
New York, NY
References
1. Grum DF, Svensson LG. Changes in cerebro-
spinal fluid pressure and spinal cord perfusion
pressure prior to cross-clamping of the thoracic
aorta in humans. J Cardiothorac Vasc Anesth.
1991;5:331-6.
2. Huynh TT, Miller CC 3rd, Estrera AL, et al.
Correlations of cerebrospinal fluid pressure
with hemodynamic parameters during thora-
coabdominal aortic aneurysm repair. Ann
Vasc Surg. 2005;19:619-24.
3. Etz CD, Homann TM, Plestis KA, et al. Spinal
cord perfusion after extensive segmental artery
sacrifice: can paraplegia be prevented? Eur
J Cardiothorac Surg. 2007;31:643-8.
4. Etz CD, Homann TM, Luehr M, et al. Spi-
nal cord blood flow and ischemic injury af-
ter experimental sacrifice of thoracic and
abdominal segmental arteries. Eur J Cardio-
thorac Surg. 2008;33:1030-8. Epub 2008
Apr 11.
doi:10.1016/j.jtcvs.2008.05.008
Letters to the Editor
The Journal of Thoracic and CardiovascuCardiac stem cells in the real
world
To the Editor:
We read with great interest the recent article
by Pouly and colleagues.1 These authors
suggest that c-kit1 cells retrieved out of hu-
man endomyocardial biopsies do not ex-
press the classic markers of stemness but
are actually mast cells. By immunofluores-
cent staining on paraffin slices they show
that c-kit1 cells are CD451 and CD1052.
Furthermore they found that these c-kit1
cells also coexpress tryptase, a granule-de-
rived serine proteinase, and as a conse-
quence appear to be mast cells.
In our experiments, right atrial appendages
were removed during routine cardiac surgery
and cultured as previously described.2 Immu-
nofluorescent staining was performed on cells
growing out of the explants after 2 weeks.
Primary labeled antibodies directed against
c-kit (phycoerythrin), CD45 (fluorescein iso-
thiocyanate [FITC]), and CD105 (FITC)
were used.A small percentage ofCD451 cells
could be detected. These CD451 cells did not
stain positive for c-kit (Figure 1, A). In con-
trast, a subpopulation of CD452 cells ex-
pressed c-kit (Figure 1, A). This is in
contradiction with the results published by
Pouly and colleagues.1 Double staining with
CD105 (FITC) and c-kit (phycoerythrin) re-
vealed that all cells in the outgrowth are
CD1051 and that a subpopulation of these
cells coexpress c-kit (Figure 1, B). These find-
ings refute that c-kit1 cells would be mast
cells (CD451, tryptase1, CD1052, and c-
kit1). Our findings are in accordance with
those published by Smith and colleagues2
andBearzi and colleagues.3 Their immunoflu-
orescence and flow cytometric analysis also
show that c-kit1 cells are CD452 but do ex-
press CD105.
Pouly and colleagues1 state that care has
to be taken that phenotypic changes could
have occurred by passaging the cells.
According to the authors, this could explain
why differences in the antigen expressing
profile are detected. In our setting, cells
were not passaged or processed; immunoflu-
orescence was performed directly on the celllar Surgery c Volume 136, Number 3 797
Letters to the EditorFigure 1. Immunofluorescent staining on cells
grown out of cardiac tissue. Cells incubated
with CD45-FITC (A, lower left) and C-kit-phycoer-
ythrin (A, upper right). 4,6-diamino-2-phenylindole
(A and B, upper left) was used to stain nuclei. A,
Outgrown c-kit1 cells do not coexpress CD45
and c-kit. B, Cells are incubated with CD105-
FITC (lower left) and c-kit-phycoerythrin (upper
right); 95% of the cells do express CD105 and
a subpopulation coexpresses c-kit. DAPI, 4,6-dia-
mino-2-phenylindole.the cell phenotype and delete some cell pop-
ulations thatdonotsurviveunderthesecondi-
tions. The latter phenomenon could explain
why Koninckx and colleagues did not find
any mast cell in their myocardial tissue cul-
tures, whereas it is well established that the
myocardium does contain such cells. Be-
causeaminorcomponentof thec-kit-positive
cells could have represented a subset of cells
different frommast cells, we also tested them
for other markers of stemness (CD105, islet-
1, andMDR1). However, in our hands, these
markers remained negative. The data of
Koninckx and colleagues suggest that after
a period of culture, c-kit-positive cardiac
‘‘stem’’ cells can be identified, but it would
beclinicallyrelevantthat theyprovideaquan-
titative estimate of these cells to assess
whether thisnumberallowsonetoreasonably
envision their use for therapeutic purposes.
Julia Pouly, MD
Patrick Bruneval, MD
Philippe Menasche, MD, PhD
Hopital Europeen Georges Pompidou
Department of Cardiovascular Surgery
Paris, France
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Aprotinin; An economy of truth?
To the Editor:
leagues3 used a propensity score that was
based on likelihood of bleeding, the FDA
reanalysis of these data used stratification
according to risk of adverse outcome. The
FDA analysis showed no increases in rela-
tive risks (RRs) for death (RR 0.91, 95%
confidence interval [CI] 0.54–1.53), heart
failure (RR 1.05, 95% CI 0.75–1.47), myo-
cardial infarction (RR 1.10, 95% CI 0.88—
1.39), or renal dysfunction (RR 1.26, 95%
CI 0.76–2.11) when data from 1222 aproti-
nin-treated patients were compared with
those of 1307 patients who did not receive
the drug.4
At the same FDA meeting, Dr Karkouti,
who used matching of pairs of data, showed
that the inclusion into the model of cardio-
pulmonary bypass variables (time and circu-
latory arrest) and transfusion (.4 units of
red blood cells and fresh-frozen plasma)
removed the statistical effects of aprotinin
on renal function.4 The Toronto data have
never shown any other mortality or morbid-
ity risk. Dr Funary also presented the North
West Consortium analysis, which showed
that any apparent effect of aprotinin on
adverse outcome is lost when red blood
cell transfusion numbers are included as
a confounding variable.5
In the article from Shaw and col-
leagues6 of the Duke University Medical
Center, the populations of patients rec-
eiving aprotinin or e-aminocaproic acidoutgrowth. So the difference in the expres-
sion profile between our c-kit1 cells and
that detected by Pouly and colleagues1 can-
not be the result of cell processing.
Our findings indicate that c-kit1 cells,
present in right atrial appendages, coexpress
CD105 but are CD452. It is therefore un-
likely that these cells are mast cells because
our data indicate that they are probably car-
diac progenitor cells.
Remco Koninckx, MSc
Karen Hensen, PhD
Jean-Luc Rummens, MD
Marc Hendrikx, MD
Virga Jesse Hospital, Hasselt, Belgium and
University of Hasselt, Diepenbeek, Belgium
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We thank Koninckx and colleagues for their
comments. As stated in our article, data
were obtained from both endomyocardial bi-
opsies and atrial appendages, and these 2
sampling sites yielded concordant data.
However, themajor difference is thatwe per-
formed in situ detection and characterization
of cells, whereas Koninckx and colleagues
cultured cells for 2 weeks before immunos-
tainings. Such a time interval can change
I write to comment on the editorials by Drs
Sundt1 (April 2008) and Westaby2 (March
2008). Dr Sundt is perceptive but fails to
consider that the observational studies sug-
gesting a danger with aprotinin may have
had bias in the analysis.
At the advisory committee meeting of
the Food and Drug Administration (FDA)
held on September 12, 2007, Dr Mangano
allowed the FDA access to the McSPI
(Multicenter Study of Perioperative Ische-
mia) data set. Whereas Mangano and col-
(EACA) were hugely different. No matter
how clever the statistical modeling, cli-
nicians will recognize that there must be
differences in management and outcome
between a patient with isolated myocardial
ischemia undergoing primary, elective
revascularization (given EACA) and one
undergoing a nonelective reoperation for
heart failure associated with valve pathol-
ogy (who would likely receive aprotinin
in about 70%-80% of cases worldwide).
Despite this, Shaw and colleagues6
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